Drug Trial Radar · NCT07903701
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,092
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of SIM0811 in participants with acute ischemic stroke who are present within 4.5 to 24 hours since last known well. The main questions it aims to answer are: 1. Does SIM0811 improve overall functional outcome, measured by the ability to perform daily activities independently without help 90 days after treatment? 2. What medical problems do participants have when taking SIM0811? Researchers will compare different doses of SIM0811 to a placebo (a look-alike substance that contains no drug) to see if SIM0811 works to treat acute ischemic stroke. Participants will: 1. Receive SIM0811 or a placebo . 2. Receive standard medical care for stroke. On the first day, all participants will also take an aspirin pill or an aspirin placebo to keep the treatment assignment a secret. 3. Stay in the hospital for a few days to undergo medical tests, including CT or MRI scans and blood draws. 4. Return to the clinic for follow-up visits for up to 90 days to check their recovery and overall health.
Conditions
- Acute Ischemic Stroke AIS
Interventions
SIM0811 Dose Level A (Phase II)Drug
Participants receive SIM0811 Dose Level A.
SIM0811 Dose Level B (Phase II)Drug
Participants receive SIM0811 Dose Level B.
SIM0811 Dose Level C (Phase II)Drug
Participants receive SIM0811 Dose Level C.
Placebo(Phase II)Drug
Participants receive SIM0811 placebo
SIM0811(Phase III)Drug
Participants receive the selected target dose of SIM0811
Placebo(Phase III)Drug
Participants receive SIM0811 placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at Day 90Time frame: Day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.